The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for antiangiogenic strategies

Journal of Cell Biology

Volumn 152, Issue 4, 2001, Pages 777-784

  Bajou, Khalid ^a   Masson, Véronique ^a   Gerard, Robert D ^b   Schmitt, Petra M ^c   Albert, Valérie ^a   Praus, Michael ^b   Lund, Leif R ^d   Frandsen, Thomas L ^d   Brunner, Nils ^d   Dano, Keld ^d   Fusenig, Norbert E ^e   Weidle, Ulrich ^f   Carmeliet, Geert ^g   Loskutoff, David ^c   Collen, Desiré ^b   Carmeliet, Peter ^b   Foidart, Jean Michel ^a   Noël, Agnès ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d FINSEN LABORATORY   (Denmark)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f ROCHE DIAGNOSTICS GMBH   (Germany)

^g UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Angiogenesis; Migration; Proteolysis; Serine protease; Tumor invasion

Indexed keywords

PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; VITRONECTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; IMMUNOFLUORESCENCE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOPEPTIDASES; ENDOTHELIUM, VASCULAR; KERATINOCYTES; MICE; MICE, MUTANT STRAINS; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; VITRONECTIN;

ANIMALIA;

EID: 0035911151     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.152.4.777     Document Type: Article

References (39)

1. The urokinase-type plasminogen activator system in cancer metastasis: A review
2. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
3. uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways?
4. Control of invasion and metastasis
5. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction
6. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice
7. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice
8. Development and disease in proteinase deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system
9. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development
10. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization
11. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis
12. Physiological consequences of loss of plasminogen activator gene function in mice
13. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice
14. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
15. Activation of plasminogen by plasma kallikrein
16. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation
17. The urokinase receptor. Protein structure and role of plasminogen activation and cancer invasion
18. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
19. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo
20. Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo
21. Adenovirus vectors
22. Coexpression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
23. Regulation of cell adhesion by PAI-1
24. Functional overlap between two classes of matrix-degrading proteases in wound healing
25. A comparison of the abilities of plasma kallikrein, beta-factor XIIa, factor Xia and urokinase to activate plasminogen
26. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
27. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
28. Angiostatin: An endogenous inhibitor of angiogenesis and of tumor growth
29. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
30. Urokinase, and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma
31. Proteolytic balance and capillary morphogenesis
32. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice
33. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
34. Mutational and immunochemical analysis of plasminogen activator inhibitor 1
35. Halting angiogenesis suppresses carcinoma cell invasion
36. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin
37. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
38. The importance of helix F in plasminogen activator-1
39. Vitronectin is not essential for normal mammalian development and fertility